About: Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99 Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 13 December 2010

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) bài báo khoa học (vi) article scientifique publié en 2010 (fr) наукова стаття, опублікована в грудні 2010 (uk) scientific article published on 13 December 2010 (en) artículu científicu espublizáu n'avientu de 2010 (ast)
publication date	wds:Q82845160-CE8898C8-D37C-4736-9A98-47409061B4A8
publication date	2010-12-13 00:00:00Z (xsd:dateTime)
author name string	wds:Q82845160-03E0D94B-D47A-4CF3-80A4-7258DFC80B4B wds:Q82845160-03EB231F-11B6-4C61-9355-D10D9EF30501 wds:Q82845160-109481F8-1A38-47D0-95C7-7565F82460C4 wds:Q82845160-15A64E71-FA28-4129-83E0-24F0D3FB110E wds:Q82845160-4EFD76FB-1BEB-423C-BA93-4AAC4E464176 wds:Q82845160-6819381B-D426-467D-89D8-C22DD74AAF70 wds:Q82845160-6992800B-B019-441D-BB3B-BD9362633264 wds:Q82845160-9B64BC16-550A-4F14-916A-DCE7563D554D wds:Q82845160-C122D7F8-0B41-42CE-8B02-A02B6A6907AD wds:Q82845160-F2983EF2-5B98-4CBB-81B7-41591AEE9156
author name string	Arnold Ganser Wolf-Karsten Hofmann Mathew Simcock André Tichelli Gert Ossenkoppele Michael Stadler Kristina Schilling Carlo Aul Aristoteles A N Giagounidis Christiane Dobbelstein
rdfs:label	Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99 (en) Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99 (nl)
skos:prefLabel	Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99 (en) Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99 (nl)
name	Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99 (en) Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99 (nl)
author	wds:Q82845160-997305A9-5B8D-4269-82CA-837CF926F9FC
author	Jakob R. Passweg
title	wds:Q82845160-AA1F9A21-EF9D-41E5-B174-D3ABA71ED956
title	Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99 (en)
page(s)	wds:Q82845160-593BA9E6-C5B9-417A-BF82-C4BC019EE79B
page(s)	303-309
instance of	wds:Q82845160-CF323E8A-E8EB-4CF8-9D65-276B423923EB
instance of	scholarly article
main subject	wds:Q82845160-15C7985A-46B9-4F3B-9699-A3E458834E92 wds:Q82845160-3C3A5459-DBED-4A2F-BA75-77F6E76D5F47 wds:Q82845160-8938D0F2-E6BB-44A1-BD1F-2C90525A58A7 wds:Q82845160-B36ED78E-CA83-414F-99B1-B093537230F6
main subject	multicenter clinical trial cyclosporine myelodysplastic syndrome phase III clinical trial
PubMed ID	wds:Q82845160-1D756342-7FCB-442A-98B5-210C0D0026C0
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21149672
PubMed ID	21149672
published in	wds:Q82845160-8E4B4EF9-1F87-4B97-AB98-CB7463F00632
published in	Journal of Clinical Oncology
issue	wds:Q82845160-D62FFFE4-0172-462C-A0B2-2F4F87B40992
volume	wds:Q82845160-10E6DB18-B80F-41F0-97DF-4629088282E3
issue	3
volume	29
DOI	wds:Q82845160-71F8F6D5-E4B9-44C0-BF91-96A72347C84F
DOI	http://dx.doi.org/10.1200/JCO.2010.31.2686
DOI	10.1200/JCO.2010.31.2686
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q82845160
is cites work of	Rare occurrence of DNMT3A mutations in myelodysplastic syndromes Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management Current therapy of myelodysplastic syndromes Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment Myelodysplastic syndromes T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS. Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes Genetic predisposition syndromes: when should they be considered in the work-up of MDS? Current treatment algorithm for the management of lower-risk MDS. Treatment of low-risk myelodysplastic syndromes Immunological derangement in hypocellular myelodysplastic syndromes EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies Infections in Myelodysplastic Syndrome in Relation to Stage and Therapy Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management [Myelodysplastic syndromes]. Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches Where Does Lenalidomide Fit in Non-del(5q) MDS? Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated? [Myelodysplastic syndromes] Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies Early Detection of Myelodysplastic Syndrome/Leukemia-associated Mutations Using NGS Is Critical in Treating Aplastic Anemia

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software